SAGE: Severe ARDS: Generating Evidence

Sponsor
Montefiore Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03021824
Collaborator
University of Michigan (Other), Duke University (Other), University of California, Los Angeles (Other)
2,400
28
6.9
85.7
12.4

Study Details

Study Description

Brief Summary

An assessment of early management of moderate-severe ARDS in the United States, including ventilator management and use of rescue therapy.

Detailed Description

Approximately one-quarter of ARDS patients develop severe hypoxemia, which has been associated with mortality rates approximating 40-50%. The majority have been described to present with severe disease at baseline, suggesting an opportunity for early intervention. In addition, use of evidence-based practices in severe ARDS is highly variable and inconsistent; use of unproven treatment modalities is also frequently seen. Given the variability in treatment practices in severe ARDS, an understanding of the patient-level and institutional-level factors contributing to differences in therapeutic approach is needed in order to improve the quality and consistency of care given to these high-risk patients. SAGE is a multicenter, observational cohort study examining the patient-level and institutional characteristics associated with variability in management of patients with moderate to severe ARDS, factors associated with survival or need for adjuvant therapy, and variability in ventilator management of patients on extracorporeal membrane oxygenation. Findings from this observational study can subsequently be used to inform future interventional trial development.

Study Design

Study Type:
Observational
Actual Enrollment :
2400 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.
Actual Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Apr 30, 2017
Actual Study Completion Date :
Apr 30, 2017

Arms and Interventions

Arm Intervention/Treatment
Moderate-Severe ARDS

All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.

Outcome Measures

Primary Outcome Measures

  1. Hospital Mortality [28 Days]

  2. Use of Adjunctive Therapy [28 Days]

Secondary Outcome Measures

  1. Ventilator-Free Days [28 Days]

  2. ICU-Free Days [28 Days]

  3. Organ Failure [7 Days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age > 18 years

  2. Patients with acute respiratory failure requiring invasive mechanical ventilation via an endotracheal tube or tracheostomy with current or planned admission to the ICU

  3. Moderate-severe ARDS as defined by fulfillment of all of the following within 48 hours:

  4. Bilateral opacities detected on chest radiograph or CT, not fully explained by effusions, lung collapse, or nodules

  5. Respiratory failure not fully explained by cardiac failure or fluid overload

  6. PaO2/FiO2 ratio < 150 with a minimum of 5 cmH20 PEEP

Exclusion Criteria:

There are no exclusion criteria.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Arizona Tucson Arizona United States 85721
2 Los Angeles County + University of Southern California Medical Center Los Angeles California United States 90033
3 University of California, Los Angeles Los Angeles California United States 90095
4 Mayo Clinic Jacksonville Florida United States 32224
5 Emory University Atlanta Georgia United States 30322
6 University of Kentucky Medical Center Lexington Kentucky United States 40536
7 Saint Agnes Hospital Baltimore Maryland United States 21229
8 Johns Hopkins University Baltimore Maryland United States 21287
9 Brigham and Women's Hospital Boston Massachusetts United States 02115
10 Beth Israel Deaconess Medical Center Boston Massachusetts United States 02215
11 Baystate Medical Center Springfield Massachusetts United States 01199
12 University of Michigan Medical Center Ann Arbor Michigan United States 48109
13 Saint Joseph Mercy Ann Arbor Ypsilanti Michigan United States 48197
14 Mayo Clinic Rochester Minnesota United States 55905
15 Regions Hospital Saint Paul Minnesota United States 55101
16 Montefiore Medical Center Bronx New York United States 10467
17 Northwell Health Manhasset New York United States 11030
18 Columbia University Medical Center New York New York United States 10032
19 Duke University Medical Center Durham North Carolina United States 27710
20 East Carolina University Greenville North Carolina United States 27834
21 University of Cincinnati Medical Center Cincinnati Ohio United States 45219
22 Cleveland Clinic Cleveland Ohio United States 44195
23 Ohio State University Medical Center Columbus Ohio United States 43210
24 Oregan Health and Science University Hospital Portland Oregon United States 97239
25 Temple University Hospital Philadelphia Pennsylvania United States 19140
26 Intermountain Medical Center Murray Utah United States 84107
27 University of Utah Hospital Salt Lake City Utah United States 84132
28 Harborview Medical Center Seattle Washington United States 98104

Sponsors and Collaborators

  • Montefiore Medical Center
  • University of Michigan
  • Duke University
  • University of California, Los Angeles

Investigators

  • Principal Investigator: Nida Qadir, MD, Montefiore Medical Center
  • Principal Investigator: Pauline Park, MD, University of Michigan
  • Principal Investigator: Raquel Bartz, MD, Duke University
  • Principal Investigator: Michelle N Gong, MD, Montefiore Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Montefiore Medical Center
ClinicalTrials.gov Identifier:
NCT03021824
Other Study ID Numbers:
  • 2016-6757
First Posted:
Jan 16, 2017
Last Update Posted:
Jan 28, 2020
Last Verified:
Dec 1, 2019

Study Results

No Results Posted as of Jan 28, 2020